Exelixis (NASDAQ:EXEL) Earns Buy Rating from Analysts at Brookline Capital Management

Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL) in a research report report published on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on EXEL. Stephens upped their price target on Exelixis from $23.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. TD Cowen increased their target price on Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Exelixis in a research report on Wednesday, September 18th. Finally, UBS Group initiated coverage on shares of Exelixis in a research note on Thursday, September 19th. They set a “neutral” rating and a $30.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $32.44.

Exelixis Stock Up 1.0 %

NASDAQ EXEL opened at $33.82 on Monday. The firm has a market capitalization of $9.66 billion, a PE ratio of 21.68, a P/E/G ratio of 0.89 and a beta of 0.52. The stock’s 50 day moving average is $33.85 and its 200 day moving average is $27.84. Exelixis has a twelve month low of $19.20 and a twelve month high of $36.97.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. During the same period in the prior year, the firm earned $0.10 EPS. The company’s revenue was up 14.3% compared to the same quarter last year. On average, research analysts anticipate that Exelixis will post 1.69 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $28.39, for a total value of $709,750.00. Following the completion of the sale, the executive vice president now directly owns 580,325 shares of the company’s stock, valued at approximately $16,475,426.75. This represents a 4.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total transaction of $352,700.00. Following the sale, the executive vice president now owns 278,665 shares in the company, valued at approximately $9,828,514.55. The trade was a 3.46 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 314,736 shares of company stock valued at $10,849,110. 2.85% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of EXEL. Covestor Ltd lifted its position in shares of Exelixis by 5.7% in the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 341 shares in the last quarter. Resonant Capital Advisors LLC lifted its holdings in Exelixis by 3.6% in the 2nd quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock worth $309,000 after purchasing an additional 477 shares in the last quarter. Cornercap Investment Counsel Inc. lifted its holdings in Exelixis by 1.1% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock worth $1,135,000 after purchasing an additional 539 shares in the last quarter. Creative Planning boosted its stake in Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock worth $1,611,000 after purchasing an additional 548 shares during the period. Finally, Advisors Asset Management Inc. raised its position in shares of Exelixis by 3.2% during the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock valued at $515,000 after buying an additional 609 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.